$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-K Financial Statement

#000145368717000014 Filed on March 28, 2017

Income Statement

Concept	2017 Q1	2016 Q4	2015 Q4
Revenue	$137.0K	$2.930M	$2.134M
YoY Change	-93.44%	37.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.880M	$5.760M	$2.030M
YoY Change	63.03%	183.74%
% of Gross Profit
Research & Development	$11.04M	$11.03M	$7.210M
YoY Change	66.13%	52.98%
% of Gross Profit
Depreciation & Amortization	$200.0K	$250.0K	$170.0K
YoY Change	12.36%	47.06%
% of Gross Profit
Operating Expenses	$14.92M	$16.79M	$9.241M
YoY Change	65.23%	81.69%
Operating Profit	-$14.78M
YoY Change	112.97%
Interest Expense	$300.0K	-$310.0K	$230.0K
YoY Change	-3.23%	-234.78%
% of Operating Profit
Other Income/Expense, Net	$0.00	$80.00K	$20.00K
YoY Change	-100.0%	300.0%
Pretax Income	-$15.13M	-$14.08M	-$6.850M
YoY Change	102.27%	105.55%
Income Tax
% Of Pretax Income
Net Earnings	-$15.13M	-$14.08M	-$6.849M
YoY Change	102.43%	105.62%
Net Earnings / Revenue	-11046.72%	-480.65%	-320.95%
Basic Earnings Per Share
Diluted Earnings Per Share	-$819.2K	-$768.1K	-$816.4K
COMMON SHARES
Basic Shares Outstanding	18.48M shares	18.19M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q4	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$68.50M	$84.10M
YoY Change	163.46%
Cash & Equivalents	$26.64M	$58.66M	$32.34M
Short-Term Investments	$41.90M	$25.50M
Other Short-Term Assets	$2.900M	$2.500M
YoY Change	26.09%
Inventory
Prepaid Expenses
Receivables	$63.00K	$215.0K	$824.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$71.49M	$86.82M	$38.91M
YoY Change	139.08%	123.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.054M	$2.047M	$2.029M
YoY Change	2.7%	0.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$122.0K	$1.566M
YoY Change	-100.0%	-92.21%
Total Long-Term Assets	$2.370M	$2.485M	$3.911M
YoY Change	-50.63%	-36.46%
TOTAL ASSETS
Total Short-Term Assets	$71.49M	$86.82M	$38.91M
Total Long-Term Assets	$2.370M	$2.485M	$3.911M
Total Assets	$73.86M	$89.30M	$42.82M
YoY Change	112.84%	108.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.317M	$3.882M	$2.179M
YoY Change	64.63%	78.16%
Accrued Expenses	$5.521M	$3.921M	$3.378M
YoY Change	97.18%	16.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.500M	$4.100M
YoY Change	542.86%
Total Short-Term Liabilities	$13.30M	$13.71M	$7.290M
YoY Change	111.17%	88.01%
LONG-TERM LIABILITIES
Long-Term Debt	$6.900M	$8.000M
YoY Change	-38.39%
Other Long-Term Liabilities	$12.60M	$0.00	$290.0K
YoY Change	293.75%	-100.0%
Total Long-Term Liabilities	$19.50M	$0.00	$290.0K
YoY Change	35.42%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.30M	$13.71M	$7.290M
Total Long-Term Liabilities	$19.50M	$0.00	$290.0K
Total Liabilities	$32.77M	$34.34M	$21.84M
YoY Change	58.29%	57.29%
SHAREHOLDERS EQUITY
Retained Earnings	-$166.7M	-$151.6M	-$111.5M
YoY Change		35.96%
Common Stock	$1.000K	$1.000K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.09M	$54.96M	-$116.5M
YoY Change
Total Liabilities & Shareholders Equity	$73.86M	$89.30M	$42.82M
YoY Change	112.84%	108.53%

Cashflow Statement

Concept	2017 Q1	2016 Q4	2015 Q4
OPERATING ACTIVITIES
Net Income	-$15.13M	-$14.08M	-$6.849M
YoY Change	102.43%	105.62%
Depreciation, Depletion And Amortization	$200.0K	$250.0K	$170.0K
YoY Change	12.36%	47.06%
Cash From Operating Activities	-$15.32M	$1.560M	-$7.640M
YoY Change	50.66%	-120.42%
INVESTING ACTIVITIES
Capital Expenditures	$58.00K	-$110.0K	-$130.0K
YoY Change	-59.44%	-15.38%
Acquisitions
YoY Change
Other Investing Activities	-$16.47M	-$5.090M	-$2.780M
YoY Change	382.99%	83.09%
Cash From Investing Activities	-$16.53M	-$5.200M	-$2.910M
YoY Change	365.04%	78.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$728.0K
YoY Change
Cash From Financing Activities	-$292.0K	2.790M	5.690M
YoY Change	-82.59%	-50.97%
NET CHANGE
Cash From Operating Activities	-$15.32M	1.560M	-7.640M
Cash From Investing Activities	-$16.53M	-5.200M	-2.910M
Cash From Financing Activities	-$292.0K	2.790M	5.690M
Net Change In Cash	-$32.02M	-850.0K	-4.860M
YoY Change	107.92%	-82.51%
FREE CASH FLOW
Cash From Operating Activities	-$15.32M	$1.560M	-$7.640M
Capital Expenditures	$58.00K	-$110.0K	-$130.0K
Free Cash Flow	-$15.37M	$1.670M	-$7.510M
YoY Change	49.13%	-122.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18480138	shares
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2016	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2016Q2	dei	Entity Public Float EntityPublicFloat	152365971	USD
CY2016	dei	Entity Registrant Name EntityRegistrantName	SELECTA BIOSCIENCES INC
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	135000	USD
CY2016Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	224000	USD
CY2015Q4	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	0	USD
CY2016Q4	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	152000	USD
CY2015Q4	selb	Accrued Legal Fees Current AccruedLegalFeesCurrent	213000	USD
CY2014	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	305000	USD
CY2016Q4	selb	Accrued Legal Fees Current AccruedLegalFeesCurrent	196000	USD
CY2015Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	219000	USD
CY2016Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	415000	USD
CY2015Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	405000	USD
CY2016Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	29000	USD
CY2015Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	1649000	USD
CY2016Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	794000	USD
CY2016Q2	selb	Class Of Warrants Or Rights Term ClassOfWarrantsOrRightsTerm	P3Y
CY2015Q4	selb	Contingently Repayable Grant Funding Current ContingentlyRepayableGrantFundingCurrent	420000	USD
CY2016Q4	selb	Contingently Repayable Grant Funding Current ContingentlyRepayableGrantFundingCurrent	0	USD
CY2016Q2	selb	Convertible Preferred Stock Warrants Fair Value Of Underlying Common Shares ConvertiblePreferredStockWarrantsFairValueOfUnderlyingCommonShares	14.00
CY2015Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	500000	USD
CY2016Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	300000	USD
CY2015Q4	selb	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	38500000	USD
CY2016Q4	selb	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	52905000	USD
CY2015Q4	selb	Deferred Tax Assets Tenant Improvement Allowance DeferredTaxAssetsTenantImprovementAllowance	0	USD
CY2016Q4	selb	Deferred Tax Assets Tenant Improvement Allowance DeferredTaxAssetsTenantImprovementAllowance	0	USD
CY2015	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	-805000	USD
CY2016	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	-461000	USD
CY2014	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	0	USD
CY2015	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	1246000	USD
CY2016	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	122000	USD
CY2014	selb	Noncash Investing And Financing Activities Issuance Of Preferred Warrants In Connection With Venture Loans NoncashInvestingAndFinancingActivitiesIssuanceOfPreferredWarrantsInConnectionWithVentureLoans	121000	USD
CY2015	selb	Noncash Investing And Financing Activities Issuance Of Preferred Warrants In Connection With Venture Loans NoncashInvestingAndFinancingActivitiesIssuanceOfPreferredWarrantsInConnectionWithVentureLoans	137000	USD
CY2016	selb	Noncash Investing And Financing Activities Issuance Of Preferred Warrants In Connection With Venture Loans NoncashInvestingAndFinancingActivitiesIssuanceOfPreferredWarrantsInConnectionWithVentureLoans	0	USD
CY2014	selb	Noncash Investing And Financing Activities Venture Debt Termination Fee Liability NoncashInvestingAndFinancingActivitiesVentureDebtTerminationFeeLiability	270000	USD
CY2015	selb	Noncash Investing And Financing Activities Venture Debt Termination Fee Liability NoncashInvestingAndFinancingActivitiesVentureDebtTerminationFeeLiability	270000	USD
CY2016	selb	Noncash Investing And Financing Activities Venture Debt Termination Fee Liability NoncashInvestingAndFinancingActivitiesVentureDebtTerminationFeeLiability	0	USD
CY2014	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	0	USD
CY2015	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	0	USD
CY2016	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	4404000	USD
CY2016Q4	selb	Number Of Warrants Exercised To Purchase Common Stock NumberOfWarrantsExercisedToPurchaseCommonStock	16493	shares
CY2014Q4	selb	Share Based Goods And Non Employee Services Transaction Compensation Not Yet Recognized Stock Options ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions	400000	USD
CY2015Q4	selb	Share Based Goods And Non Employee Services Transaction Compensation Not Yet Recognized Stock Options ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions	100000	USD
CY2016Q4	selb	Share Based Goods And Non Employee Services Transaction Compensation Not Yet Recognized Stock Options ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions	1100000	USD
CY2016Q4	selb	Stock Issued During Period Shares Common Stock Issued Upon Exercise Of Warrants StockIssuedDuringPeriodSharesCommonStockIssuedUponExerciseOfWarrants	4697	shares
CY2016	selb	Stock Issued During The Period Value Warrants Exercised StockIssuedDuringThePeriodValueWarrantsExercised	0	USD
CY2014	selb	Stock Vested During Period Value Restricted Common Stock StockVestedDuringPeriodValueRestrictedCommonStock	69000	USD
CY2015	selb	Stock Vested During Period Value Restricted Common Stock StockVestedDuringPeriodValueRestrictedCommonStock	23000	USD
CY2016	selb	Stock Vested During Period Value Restricted Common Stock StockVestedDuringPeriodValueRestrictedCommonStock	21000	USD
CY2014	selb	Stockholders Equity Accretion To Redemption Value StockholdersEquityAccretionToRedemptionValue	4951000	USD
CY2015	selb	Stockholders Equity Accretion To Redemption Value StockholdersEquityAccretionToRedemptionValue	7335000	USD
CY2016	selb	Stockholders Equity Accretion To Redemption Value StockholdersEquityAccretionToRedemptionValue	4566000	USD
CY2016Q4	selb	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2179000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3882000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	824000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	215000	USD
CY2014	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2015	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-193000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3378000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3921000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2927000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3740000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4986000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4518000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	211125000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1224000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1125000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2030000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1224000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1125000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2051000	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7631689	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12137409	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2225648	shares
CY2015Q4	us-gaap	Assets Assets	42824000	USD
CY2016Q4	us-gaap	Assets Assets	89301000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	38913000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	86816000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	3516000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	24785000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	53000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	3516000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	24821000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	3516000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	24821000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	3516000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	24785000	USD
CY2016Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	6	position
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	20	position
CY2014	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	147000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8057000	USD
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	62164377	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2180976	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18438742	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2173399	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18438742	shares
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16592000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32337000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58656000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8535000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15745000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	26319000	USD
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	17.55
CY2015Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	315198	shares
CY2016Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	80813	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12826886	shares
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3164965	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16161000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26284000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35742000	USD
CY2016Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	10126118	shares
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7288000	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	2022000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1725000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	105000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	222000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1313000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1836000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2295000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12439000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1582000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5607000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	114000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	3500000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4934000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	40522000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	54630000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31958000	USD
CY2014	us-gaap	Depreciation Depreciation	900000	USD
CY2014	us-gaap	Depreciation Depreciation	864000	USD
CY2015	us-gaap	Depreciation Depreciation	1000000	USD
CY2016	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	800000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	97000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	69000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	197000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	131000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Unrealized Currency Transaction Gains DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains	1728000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Unrealized Currency Transaction Gains DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains	1525000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39420000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2305000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3052000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	570000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	904000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	493000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	713000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38500000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52905000	USD
CY2015	us-gaap	Depreciation Depreciation	1044000	USD
CY2016	us-gaap	Depreciation Depreciation	802000	USD
CY2016	us-gaap	Depreciation Depreciation	800000	USD
CY2016	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.84
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.43
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.93
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.50
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.26
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-15.13
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.52
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.75
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.89
CY2014	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-3323000	USD
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1019000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	443000	USD
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.330
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.400
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.398
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.007
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.011
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.078
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.059
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.057
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.058
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.016
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.010
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.007
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.013
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	669000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1551000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	38000	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-83000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12000	USD
CY2014	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3004000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	933000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-525000	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7953000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8335000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13051000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-90000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	667000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2686000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	514000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	153000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-610000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	415000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1259000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	716000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-20000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-507000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10409000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	404000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1011000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	860000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	1779000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-977000	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-103000	USD
CY2014	us-gaap	Interest Expense InterestExpense	552000	USD
CY2015	us-gaap	Interest Expense InterestExpense	948000	USD
CY2016	us-gaap	Interest Expense InterestExpense	1253000	USD
CY2014	us-gaap	Interest Paid InterestPaid	366000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	34000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	81000	USD
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	111000	USD
CY2015	us-gaap	Interest Paid InterestPaid	531000	USD
CY2016	us-gaap	Interest Paid InterestPaid	972000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	21835000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	34344000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42824000	USD
CY2015	us-gaap	Investment Income Net InvestmentIncomeNet	171000	USD
CY2016	us-gaap	Investment Income Net InvestmentIncomeNet	234000	USD
CY2014	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
CY2015	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
CY2016	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	36000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89301000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7290000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13706000	USD
CY2015Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	USD
CY2016Q4	us-gaap	Loans Payable Current LoansPayableCurrent	4067000	USD
CY2015Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	11855000	USD
CY2016Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	7977000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	24771000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	43906000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	67659000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-227000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-4679000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-22100000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12686000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22463000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19683000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-12880000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-5733000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-6867000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-5725000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-6849000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-25174000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-7476000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-6923000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-7728000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-14083000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-36210000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16372000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7294000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8429000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7561000	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9225000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32509000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9832000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9133000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7728000	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14083000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40776000	USD
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2014	us-gaap	Operating Expenses OperatingExpenses	18439000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	6844000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	42753000	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	7552000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	7678000	USD
CY2015Q4	us-gaap	Operating Expenses OperatingExpenses	9241000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	31315000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	9029000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	8418000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	8516000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	16790000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-15399000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-25304000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-34670000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4200000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1244000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	335000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1330000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1291000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1100000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1600000	USD
CY2014	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	700000	USD
CY2015	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	200000	USD
CY2016	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	0	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	54000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	479000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1566000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	122000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3281000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1110000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	504000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	468000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-36000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	290000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-44000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000	USD
CY2016	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2014	us-gaap	Paid In Kind Interest PaidInKindInterest	155000	USD
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	198000	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	263000	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	302000	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4103000	USD
CY2015	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	7335000	USD
CY2016	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4566000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	227000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1163000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	586000	USD
CY2014	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	3516000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-87755000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-116493000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	54957000	USD
CY2016Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.2564
CY2014	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4951000	USD
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	28416000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	1459000	USD
CY2015Q1	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2015Q2	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2015Q3	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2015Q4	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2015	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2016Q1	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2016Q2	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2016Q3	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2016Q4	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2016	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	0	USD
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1494000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2382000	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7092000	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	68870000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2743000	USD
CY2014	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	20140000	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	32669000	USD
CY2016	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2014	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	4494000	USD
CY2015	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	6674000	USD
CY2016	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2014	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2015	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	6900000	USD
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	137000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29702000	USD
CY2014	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2014	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	4951000	USD
CY2015Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1561000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	109000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	149000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4956000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5787000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2029000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2047000	USD
CY2014	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2015	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2016	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2015Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	0	USD
CY2016Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	75000	USD
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2336000	USD
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10486000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22980000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	133000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	78000	USD
CY2015Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111508000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111500000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151576000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151600000	USD
CY2014	us-gaap	Revenues Revenues	3040000	USD
CY2015Q1	us-gaap	Revenues Revenues	1034000	USD
CY2015Q2	us-gaap	Revenues Revenues	1236000	USD
CY2015Q3	us-gaap	Revenues Revenues	1607000	USD
CY2015Q4	us-gaap	Revenues Revenues	2134000	USD
CY2015	us-gaap	Revenues Revenues	6011000	USD
CY2016Q1	us-gaap	Revenues Revenues	2088000	USD
CY2016Q2	us-gaap	Revenues Revenues	2017000	USD
CY2016Q3	us-gaap	Revenues Revenues	1048000	USD
CY2016Q4	us-gaap	Revenues Revenues	2930000	USD
CY2016	us-gaap	Revenues Revenues	8083000	USD
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	4125000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	25485000	USD
CY2015	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	3647000	USD
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1459000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	142048000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	64465000	USD
CY2016	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	2743000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	86000	USD
CY2015Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1562000	USD
CY2015Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1836000	USD
CY2015Q4	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2376000	USD
CY2015	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	0	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	149000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-69463000	USD
CY2015	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	7335000	USD
CY2016Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2356000	USD
CY2015Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	137482000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	USD
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	10100000	USD
CY2016Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2210000	USD
CY2015Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	37835623	shares
CY2016Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2014	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	0	USD
CY2016Q4	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2016	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	4566000	USD
CY2016Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2016Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2014Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	28804969	shares
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14400000	USD
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2090677	shares
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2126878	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2147184	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2159658	shares
CY2015Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2167769	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2150422	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2175037	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3322546	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18108014	shares
CY2016Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18265771	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10493939	shares
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk and Off‑Balance Sheet Risk</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars.</font></div></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, the fair value of common stock and other equity instruments, accounting for stock-based compensation, income taxes, collectability of accounts receivable, useful lives of long-lived assets, accrued expenses, and accounting for project development. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s management made significant estimates and assumptions in determining the fair value of its common stock for those periods reported prior to the completion of the IPO. The Company utilized various valuation methodologies in accordance with the framework of the 2004 American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology included estimates and assumptions that require the Company’s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.</font></div></div>

Files In Submission

Name	View Source	Status
0001453687-17-000014-index-headers.html	Edgar Link	pending
0001453687-17-000014-index.html	Edgar Link	pending
0001453687-17-000014.txt	Edgar Link	pending
0001453687-17-000014-xbrl.zip	Edgar Link	pending
exhibit231123116.htm	Edgar Link	pending
exhibit311123116.htm	Edgar Link	pending
exhibit312123116.htm	Edgar Link	pending
exhibit321123116.htm	Edgar Link	pending
exhibit322123116.htm	Edgar Link	pending
figure10.jpg	Edgar Link	pending
figure11.jpg	Edgar Link	pending
figure12.jpg	Edgar Link	pending
figure13.jpg	Edgar Link	pending
figure14.jpg	Edgar Link	pending
figure15.jpg	Edgar Link	pending
figure16.jpg	Edgar Link	pending
figure17.jpg	Edgar Link	pending
figure18.jpg	Edgar Link	pending
figure1a02.jpg	Edgar Link	pending
figure1apipelinea01.jpg	Edgar Link	pending
figure1botherprojects.jpg	Edgar Link	pending
figure2.jpg	Edgar Link	pending
figure24v2.jpg	Edgar Link	pending
figure26v2.jpg	Edgar Link	pending
figure3.jpg	Edgar Link	pending
figure30a.jpg	Edgar Link	pending
figure30b.jpg	Edgar Link	pending
figure33.jpg	Edgar Link	pending
figure34.jpg	Edgar Link	pending
figure39.jpg	Edgar Link	pending
figure40.jpg	Edgar Link	pending
figure41.jpg	Edgar Link	pending
figure43.jpg	Edgar Link	pending
figure44.jpg	Edgar Link	pending
figure46.jpg	Edgar Link	pending
figure47.jpg	Edgar Link	pending
figure48.jpg	Edgar Link	pending
figure49.jpg	Edgar Link	pending
figure4a02.jpg	Edgar Link	pending
figure52.jpg	Edgar Link	pending
figure53.jpg	Edgar Link	pending
figure54.jpg	Edgar Link	pending
figure5a01.jpg	Edgar Link	pending
figure6.jpg	Edgar Link	pending
figure7.jpg	Edgar Link	pending
figure8.jpg	Edgar Link	pending
figure9.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image27c.jpg	Edgar Link	pending
newfigure25a.jpg	Edgar Link	pending
newfigure25b.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20161231.xml	Edgar Link	completed
selb-20161231.xsd	Edgar Link	pending
selb-20161231_cal.xml	Edgar Link	unprocessable
selb-20161231_def.xml	Edgar Link	unprocessable
selb-20161231_lab.xml	Edgar Link	unprocessable
selb-20161231_pre.xml	Edgar Link	unprocessable
selectabiosciences10-k1231.htm	Edgar Link	pending
Show.js	Edgar Link	pending
stockperformancechart.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2017 Q1 Form 10-K Financial Statement

#000145368717000014 Filed on March 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2017 Q1 Form 10-K Financial Statement

#000145368717000014 Filed on March 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac